Protalix BioTherapeutics, Inc. (PLX) Earnings History
Annual and quarterly earnings data from 1996 to 2025
Loading earnings history...
PLX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PLX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 48.8% | -10.4% | -12.5% |
| 2024 | 54.5% | 7.3% | 5.5% |
| 2023 | 64.9% | 16.0% | 12.7% |
| 2022 | 58.9% | -27.3% | -31.3% |
| 2021 | 57.4% | -53.4% | -71.9% |
Download Data
Export PLX earnings history in CSV or JSON format
Free sign-in required to download data
Protalix BioTherapeutics, Inc. (PLX) Earnings Overview
As of May 8, 2026, Protalix BioTherapeutics, Inc. (PLX) reported trailing twelve-month net income of -$7M, reflecting -329.8% year-over-year growth. The company earned $-0.08 per diluted share over the past four quarters, with a net profit margin of -12.5%.
Looking at the long-term picture, PLX's historical earnings data spans multiple years. The company achieved its highest annual net income of $58M in fiscal 2015.
Protalix BioTherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), SRPT ($65M net income, -32.5% margin), PLX has outperformed on profitability metrics. Compare PLX vs RARE →
PLX Earnings vs Peers
Earnings metrics vs comparable public companies
PLX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$7M | -325.2% | -$6M | $-0.08 | -12.5% | -10.4% |
| 2024 | $3M | -64.7% | $4M | $0.04 | 5.5% | 7.3% |
| 2023 | $8M | +155.7% | $10M | $0.10 | 12.7% | 16.0% |
| 2022 | -$15M | +45.9% | -$13M | $-0.31 | -31.3% | -27.3% |
| 2021 | -$28M | -322.8% | -$20M | $-0.62 | -71.9% | -53.4% |
| 2020 | -$7M | +64.3% | $3M | $-0.22 | -10.4% | 4.3% |
| 2019 | -$18M | +30.9% | -$11M | $-1.23 | -33.4% | -19.6% |
| 2018 | -$26M | +68.3% | -$19M | $-1.80 | -77.3% | -56.4% |
| 2017 | -$83M | -184.1% | -$35M | $-6.50 | -395.9% | -163.8% |
| 2016 | -$29M | -150.6% | -$33M | $-0.29 | -319.2% | -360.5% |
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PLX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPLX — Frequently Asked Questions
Quick answers to the most common questions about buying PLX stock.
Is PLX growing earnings?
PLX EPS fell to $-0.08, with earnings declining -329.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-7M.
What are PLX's profit margins?
Protalix BioTherapeutics, Inc. net margin is -12.5%, with operating margin at -10.4%. Below-average margins reflect competitive or cost pressures.
How consistent are PLX's earnings?
PLX earnings data spans 1996-2025. The declining earnings trend is -329.8% YoY. Historical data enables comparison across business cycles.